Form 4: BioMarin Executive Reports Stock Disposition

BioMarin Pharmaceutical Inc. EVP and Chief Commercial Officer Cristin Hubbard disposed of 2,318 shares of common stock to cover tax obligations.

Summary

• Cristin Hubbard, EVP and Chief Commercial Officer of BioMarin Pharmaceutical Inc., executed a transaction on May 20, 2026.
• The transaction involved the disposition of 2,318 shares of common stock at a price of $50.20 per share.
• The shares were disposed of to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 42,472 shares of BioMarin common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is purely administrative and related to tax compliance rather than a change in executive sentiment regarding the company's prospects.

Positives

• The transaction was a routine administrative action related to tax withholding rather than a discretionary sale of shares.

Negatives

• Reduction in the total number of shares held directly by a key executive.

Risks

• None identified; this is a standard regulatory filing for executive compensation tax compliance.

Future Outlook

No forward-looking guidance or strategic outlook provided in this filing.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard practice for corporate executives in the biotechnology sector to satisfy statutory tax obligations upon the vesting of restricted stock units.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices observed at peer companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine tax-related withholding.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Executive Compensation, Biotech